Integrin targeted drug and gene delivery

Bibliography

• Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des 2009;15(17):1949-55
   PubMed Web of Science ®Google Scholar
• Pavalko FM, Otey CA. Role of adhesion molecule cytoplasmic domains in mediating interactions with the cytoskeleton. Proc Soc Exp Biol Med 1994;205(4):282-93
   PubMed Web of Science ®Google Scholar
• Christofori G. Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J 2003;22(10):2318-23
   PubMed Web of Science ®Google Scholar
• Vyas SP, Vaidya B. Targeted delivery of thrombolytic agents: role of integrin receptors. Expert Opin Drug Deliv 2009;6(5):499-508
   PubMed Web of Science ®Google Scholar
• Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004;114(5-6):447-53
   PubMed Web of Science ®Google Scholar
• Alvarez-Rodriguez L, Ruiz M, Marin MJ, Adhesion molecules expression and chemotactic ability of peripheral blood leukocytes in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 2008;58(9):S394-5
   Web of Science ®Google Scholar
• Banquy X, Leclair G, Rabanel JM, Selectins ligand decorated drug carriers for activated endothelial cell targeting. Bioconjug Chem 2008;19(10):2030-9
   PubMed Web of Science ®Google Scholar
• Ichinose K, Kawasaki E, Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 2007;27(6):554-64
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110(6):673-87
   PubMed Web of Science ®Google Scholar
• Giancotti FG, Ruoslahti E. Transduction - integrin signaling. Science 1999;285(5430):1028-32
   PubMed Web of Science ®Google Scholar
• Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2(2):91-100
   PubMed Web of Science ®Google Scholar
• Eble JA, Haier J. Integrins in cancer treatment. Curr Cancer Drug Targets 2006;6(2):89-105
   PubMed Web of Science ®Google Scholar
• Sastry SK, Burridge K. Focal adhesions: a nexus for intracellular signaling and cytoskeletal dynamics. Exp Cell Res 2000;261(1):25-36
   PubMed Web of Science ®Google Scholar
• Burridge K, Wodnicka MC. Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 1996;12:463-518
   PubMed Web of Science ®Google Scholar
• Dunehoo AL, Anderson M, Majumdar S, Cell adhesion molecules for targeted drug delivery. J Pharm Sci 2006;95(9):1856-72
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins - versatility, modulation, and signaling in cell-adhesion. Cell 1992;69(1):11-25
   PubMed Web of Science ®Google Scholar
• Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration - the multistep paradigm. Cell 1994;76(2):301-14
   PubMed Web of Science ®Google Scholar
• Curley GP, Blum H, Humphries MJ. Integrin antagonists. Cell Mol Life Sci 1999;56(5-6):427-41
   PubMed Web of Science ®Google Scholar
• Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2(9):703-16
   PubMed Web of Science ®Google Scholar
• Coller BS. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest 1997;100(11):S57-60
   PubMed Web of Science ®Google Scholar
• Trikha M, Zhou Z, Timar J, Multiple roles for platelet GPIIb/IIIa and alpha v beta 3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002;62(10):2824-33
   PubMed Web of Science ®Google Scholar
• Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta(3) integrins. Circulation 1998;98(11):1085-91
   PubMed Web of Science ®Google Scholar
• Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin alpha(V)beta(3) for angiogenesis. Science 1994;264(5158):569-71
   PubMed Web of Science ®Google Scholar
• Nakada MT, Cao G, Sassoli PM, DeLisser HM. c7E3 Fab inhibits human tumor angiogenesis in a SCID mouse human skin xenograft model. Angiogenesis 2006;9(4):171-6
   PubMedGoogle Scholar
• Califf RM, Shadoff N, Valett N, Use of a monoclonal-antibody directed against the platelet glycoprotein Iib/Iiia receptor in high-risk coronary angioplasty. N Engl J Med 1994;330(14):956-61
   PubMed Web of Science ®Google Scholar
• Topol EJ, Califf RM, Weisman HF, Randomized trial of coronary intervention with antibody against platelet Iib/Iiia integrin for reduction of clinical restenosis - results at 6 months. Lancet 1994;343(8902):881-6
   PubMed Web of Science ®Google Scholar
• Cheresh DA. Human-endothelial cells synthesize and express an arg-gly-asp-directed adhesion receptor involved in attachment to fibrinogen and vonwillebrand-factor. Proc Natl Acad Sci USA 1987;84(18):6471-5
   PubMed Web of Science ®Google Scholar
• Friedlander M, Brooks PC, Shaffer RW, Definition of 2 angiogenic pathways by distinct alpha(V) integrins. Science 1995;270(5241):1500-2
   PubMed Web of Science ®Google Scholar
• Brooks PC, Stromblad S, Klemke R, Antiintegrin alpha-v-beta-3 blocks human breast-cancer growth and angiogenesis in human skin. J Clin Invest 1995;96(4):1815-22
   PubMed Web of Science ®Google Scholar
• Brooks PC, Montgomery AMP, Rosenfeld M, Integrin alpha-v-beta-3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994 1994;79(7):1157-64
   Google Scholar
• Rader C, Popkov M, Neves JA, Barbas CF. Integrin alpha v beta 3-targeted therapy for Kaposi's sarcoma with an in vitro-evolved antibody. FASEB J 2002;16(12):2000
   PubMed Web of Science ®Google Scholar
• Posey JA, Khazaeli MB, DelGrosso A, A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti alpha(v)beta(3)) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001;16(2):125-32
   PubMed Web of Science ®Google Scholar
• Liu ZF, Wang F, Chen XY. Integrin alpha(v)beta(3)-targeted cancer therapy. Drug Dev Res 2008;69(6):329-39
   PubMed Web of Science ®Google Scholar
• Trikha M, Zhou Z, Nemeth JA, CNTO 95, a fully human monoclonal antibody that inhibits alpha v integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004;110(3):326-35
   PubMed Web of Science ®Google Scholar
• Chen QM, Manning CD, Millar H, CNTO 95, a fully human anti alpha v integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis 2008;25(2):139-48
   PubMed Web of Science ®Google Scholar
• Mullamitha SA, Ton NC, Parker GJM, Phase I evaluation of a fully human anti-alpha(v) integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 2007;13(7):2128-35
   PubMed Web of Science ®Google Scholar
• Ning SC, Nemeth JA, Hanson RL, Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther 2008;7(6):1569-78
   PubMed Web of Science ®Google Scholar
• Mitjans F, Sander D, Adan J, An anti-alpha-v-integrin antibody that blocks integrin function inhibits the development of a human-melanoma in nude-mice. J Cell Sci 1995;108:2825-38
   PubMed Web of Science ®Google Scholar
• Mitjans F, Meyer T, Fittschen C, In vivo therapy of malignant melanoma by means of antagonists of alpha v integrins. Int J Cancer 2000;87(5):716-23
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Pierschbacher MD. Arg-gly-asp - a versatile cell recognition signal. Cell 1986;44(4):517-8
   PubMed Web of Science ®Google Scholar
• Marinelli L, Lavecchia A, Gottschalk KE, Docking studies on alpha(v)beta(3) integrin ligands: pharmacophore refinement and implications for drug design. J Med Chem 2003;46(21):4393-404
   PubMed Web of Science ®Google Scholar
• Kopple KD, Baures PW, Bean JW, Conformations of arg-gly-asp containing heterodetic cyclic-peptides - solution and crystal studies. J Am Chem Soc 1992;114(24):9615-23
   Web of Science ®Google Scholar
• Dechantsreiter MA, Planker E, Matha B, N-methylated cyclic RGD peptides as highly active and selective alpha(v)beta(3) integrin antagonists. J Med Chem 1999;42(16):3033-40
   PubMed Web of Science ®Google Scholar
• MacDonald TJ, Stewart CF, Kocak M, Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012. J Clin Oncol 2008;26(6):919-24
   PubMed Web of Science ®Google Scholar
• Eskens F, Dumez H, Hoekstra R, Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alpha v beta 3 and alpha v beta 5 in patients with advanced solid tumours. Eur J Cancer 2003;39(7):917-26
   PubMed Web of Science ®Google Scholar
• Beekman KW, Colevas AD, Cooney K, Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design. Clin Genitourin Cancer 2006;4(4):299-302
   PubMed Web of Science ®Google Scholar
• Friess H, Langrehr JM, Oettle H, A randomized multi-center phase II trial of the angiogenesis inhibitor cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 2006;6:285
   PubMed Web of Science ®Google Scholar
• Nabors LB, Mikkelsen T, Rosenfeld SS, Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007;25(13):1651-7
   PubMed Web of Science ®Google Scholar
• Khalili P, Arakelian A, Chen GP, A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006;5(9):2271-80
   PubMed Web of Science ®Google Scholar
• Livant DL, Brabec RK, Pienta KJ, Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 2000;60(2):309-20
   PubMed Web of Science ®Google Scholar
• Stoeltzing O, Liu WB, Reinmuth N, Inhibition of integrin alpha(5)beta(1) function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003;104(4):496-503
   PubMed Web of Science ®Google Scholar
• Donate F, Parry GC, Shaked Y, Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res 2008;14(7):2137-44
   PubMed Web of Science ®Google Scholar
• Cianfrocca ME, Kimmel KA, Gallo J, Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006;94(11):1621-6
   PubMed Web of Science ®Google Scholar
• Thibault G, Tardif P, Lapalme G. Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists. J Pharmacol Exp Ther 2001;296(3):690-6
   PubMed Web of Science ®Google Scholar
• Lal H, Guleria RS, Foster DM, Integrins: novel therapeutic targets for cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 2007;5(2):109-32
   PubMedGoogle Scholar
• Yusuf-Makagiansar H, Makagiansar IT, Hu YB, Siahaan TJ. Synergistic inhibitory activity of alpha- and beta-LFA-1 peptides on LFA-1/ICAM-1 interaction. Peptides 2001;22(12):1955-62
   PubMed Web of Science ®Google Scholar
• Tibbetts SA, Chirathaworn C, Nakashima M, Peptides derived from ICAM-1 and LFA-1 modulate T cell adhesion and immune function in a mixed lymphocyte culture. Transplantation 1999;68(5):685-92
   PubMed Web of Science ®Google Scholar
• Yusuf-Makagiansar H, Siahaan TJ. Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells. Pharm Res 2001;18(3):329-35
   PubMed Web of Science ®Google Scholar
• Lu X, Lu D, Scully MF, Kakkar VV. Integrins in drug targeting-RGD templates in toxins. Curr Pharm Des 2006;12(22):2749-69
   PubMed Web of Science ®Google Scholar
• McLane MA, VijayKumar S, Marcinkiewicz C, Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. FEBS Lett 1996;391(1-2):139-43
   PubMed Web of Science ®Google Scholar
• Okuda D, Koike H, Morita T. A new gene structure of the disintegrin family: a subunit of dimeric disintegrin has a short coding region. Biochemistry 2002;41(48):14248-54
   PubMed Web of Science ®Google Scholar
• Huang TF, Holt JC, Lukasiewicz H, Niewiarowski S. Trigramin - a low-molecular-weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein-Iib-Iiia complex. J Biol Chem 1987;262(33):16157-63
   PubMed Web of Science ®Google Scholar
• Horton DA, Bourne GT, Smythe ML. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem Rev 2003;103(3):893-930
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-9
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279(5349):377-80
   PubMed Web of Science ®Google Scholar
• Kim JW, Lee HS. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model. Int J Mol Med 2004;14(4):529-35
   PubMed Web of Science ®Google Scholar
• Burkhart DJ, Kalet BT, Coleman MP, Doxorubicin-formaldehyde conjugates targeting alpha(v)beta(3) integrin. Mol Cancer Ther 2004;3(12):1593-604
   PubMed Web of Science ®Google Scholar
• Chen XY, Plasencia C, Hou YP, Neamati N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 2005;48(4):1098-106
   PubMed Web of Science ®Google Scholar
• Cao QZ, Li ZB, Chen K, Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur J Nucl Med Mol Imaging 2008;35(8):1489-98
   PubMed Web of Science ®Google Scholar
• Ellerby HM, Arap W, Ellerby LM, Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5(9):1032-8
   PubMed Web of Science ®Google Scholar
• Chen YX, Xu XM, Hong SG, RGD-tachyplesin inhibits tumor growth. Cancer Res 2001;61(6):2434-8
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Ramakrishnan S. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int J Cancer 2004;111(6):839-48
   PubMed Web of Science ®Google Scholar
• Curnis F, Gasparri A, Sacchi A, Coupling tumor necrosis factor-alpha with alpha(v) integrin ligands improves its antineoplastic activity. Cancer Res 2004;64(2):565-71
   PubMed Web of Science ®Google Scholar
• Sacchi A, Gasparri A, Curnis F, Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 2004;64(19):7150-5
   PubMed Web of Science ®Google Scholar
• Xiao B, Li W, Yang J, RGD-IL-24, a novel tumor-targeted fusion cytokine: expression, purification and functional evaluation. Mol Biotechnol 2009;41(2):138-44
   PubMed Web of Science ®Google Scholar
• Bieker R, Kessler T, Schwoppe C, Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 2009;113(20):5019-27
   PubMed Web of Science ®Google Scholar
• Dickerson EB, Akhtar N, Steinberg H, Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alpha(v)beta(3) integrin. Mol Cancer Res 2004;2(12):663-73
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12):6387-92
   PubMed Web of Science ®Google Scholar
• Wang Z, Chui WK, Ho PC. Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm Res 2009;26(5):1162-71
   PubMed Web of Science ®Google Scholar
• Murphy EA, Majeti BK, Barnes LA, Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008;105(27):9343-8
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 2005;107(2):262-75
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 2005;94(8):1782-93
   PubMed Web of Science ®Google Scholar
• Dubey PK, Mishra V, Jain S, Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target 2004;12(5):257-64
   PubMed Web of Science ®Google Scholar
• Holig P, Bach M, Volkel T, Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng Des Sel 2004;17(5):433-41
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang JC, Sun QS, RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target 2009;17(1):10-8
   PubMed Web of Science ®Google Scholar
• Pattillo CB, Sari-Sarraf F, Nallamothu R, Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm Res 2005;22(7):1117-20
   PubMed Web of Science ®Google Scholar
• Sen Gupta A, Huang G, Lestini BJ, RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb Haemost 2005;93(1):106-14
   PubMed Web of Science ®Google Scholar
• Lestini BJ, Sagnella SM, Xu Z, Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release 2002;78(1-3):235-47
   PubMed Web of Science ®Google Scholar
• Nasongkla N, Shuai X, Ai H, cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed 2004;43(46):6323-7
   PubMed Web of Science ®Google Scholar
• Nasongkla N, Bey E, Ren JM, Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett 2006;6(11):2427-30
   PubMed Web of Science ®Google Scholar
• Deng C, Chen XS, Sun J, RGD peptide grafted biodegradable amphiphilic triblock copolymer poly(glutamic acid)-b-poly(L-lactide)-b-poly(glutamic acid): synthesis and self-assembly. J Poly Sci A Poly Chem 2007;45(15):3218-30
   Web of Science ®Google Scholar
• Shen SI, Kotamraj PR, Bhattacharya S, Synthesis and characterization of RGD-fatty acid amphiphilic micelles as targeted delivery carriers for anticancer agents. J Drug Target 2007;15(1):51-8
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YS, Park K, Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 2008;29(12):1920-30
   PubMed Web of Science ®Google Scholar
• Swenson S, Costa F, Minea R, Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol Cancer Ther 2004;3(4):499-511
   PubMed Web of Science ®Google Scholar
• Hood JD, Bednarski M, Frausto R, Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296(5577):2404-7
   PubMed Web of Science ®Google Scholar
• Pramanik D, Majeti BK, Mondal G, Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic alpha 5 beta 1 integrin receptor and mouse tumor vasculature. J Med Chem 2008;51(22):7298-302
   PubMed Web of Science ®Google Scholar
• Erbacher P, Remy JS, Behr JP. Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway. Gene Ther 1999;6(1):138-45
   PubMed Web of Science ®Google Scholar
• Kim WJ, Yockman JW, Lee M, Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J Control Release 2005;106(1-2):224-34
   PubMed Web of Science ®Google Scholar
• Suh W, Han SO, Yu L, Kim SW. An angiogenic, endothelial-cell-targeted polymeric gene carrier. Mol Ther 2002;6(5):664-72
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Ansari A, Xu J, Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32(19)
   PubMed Web of Science ®Google Scholar
• Kang H, Alam MR, Dixit V, Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier. Bioconjug Chem 2008;19(11):2182-8
   PubMed Web of Science ®Google Scholar
• Harbottle RP, Cooper RG, Hart SL, An RGD-oligolysine peptide: a prototype construct for integrin-mediated gene delivery. Hum Gene Ther 1998;9(7):1037-47
   PubMed Web of Science ®Google Scholar
• Skuli N, Monferran S, Delmas C, alpha(v)beta(3)/alpha(v)beta(5) integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 2009;69(8):3308-16
   PubMed Web of Science ®Google Scholar
• Zhang XP, Fournier MV, Ware JL, Inhibition of vimentin or beta(1) integrin revert morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther 2009;8(3):499-508
   PubMed Web of Science ®Google Scholar
• Lipscomb EA, Dugan AS, Rabinovitz I, Mercurio AM. Use of RNA interference to inhibit integrin (alpha 6 beta 4)-mediated invasion and migration of breast carcinoma cells. Clin Exp Metastasis 2003;20(6):569-76
   PubMed Web of Science ®Google Scholar
• Peer D, Shimaoka M. Systemic siRNA delivery to leukocyte-implicated diseases. Cell Cycle 2009;8(6):853-9
   PubMed Web of Science ®Google Scholar
• Kim SS, Peer D, Kumar P, siRNA delivery with integrin LFA-1-targeted nanoparticles prevents hiv infection in humanized mice. Clin Immunol 2009;131:S75-6
   Web of Science ®Google Scholar
• Bhattacharyya J, Mondal G, Madhusudana K, Single subcutaneous administration of RGDK-lipopeptide:rhPDGF-B gene complex heals wounds in streptozotocin-induced diabetic rats. Mol Pharm 2009;6(3):918-27
   PubMed Web of Science ®Google Scholar
• Peer D, Park EJ, Morishita Y, Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008;319(5863):627-30
   PubMed Web of Science ®Google Scholar
• Toh ML, Hong AS, van de Loo F, Enhancement of adenovirus-mediated gene delivery to rheumatoid arthritis synoviocytes and synovium by fiber modifications: role of arginine-glycine-aspartic acid (RGD)and non-RGD-binding integrins. J Immunol 2005;175(11):7687-98
   PubMed Web of Science ®Google Scholar
• Harvie P, Dutzar B, Galbraith T, Targeting of lipid-protamine-DNA (LPD) lipopolyplexes using RGD motifs. J Liposome Res 2003;13(3-4):231-47
   PubMed Web of Science ®Google Scholar
• Zugates GT, Anderson DG, Little SR, Synthesis of poly(beta-amino ester)s with thiol-reactive side chains for DNA delivery. J Am Chem Soc 2006;128(39):12726-34
   PubMed Web of Science ®Google Scholar
• Green JJ, Chiu E, Leshchiner ES, Electrostatic ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary cells. Nano Lett 2007;7(4):874-9
   PubMed Web of Science ®Google Scholar